Abstract WP253: Cystatin C and the Risk of Cardioembolic Stroke in Patients Without Chronic Kidney Disease

Abstract

Background and Objectives: Atrial fibrillation (AF) is well-established risk factor for cardioembolic stroke. Epidemiological evidence indicates that there is increased risk of AF with chronic kidney disease (CKD) and impaired renal function. Cystatin C (Cys-C) is now considered as a specific marker for detection of renal impairment. However, there are no data about the potential association of Cys-C with AF and cardioembolic stroke in the subjects without evident CKD. We investigated whether serum Cys-C level is associated with development of cardioembolic stroke in patients with AF. Methods: Consecutive data were collected retrospectively at the Seoul National University Hospital (SNUH). Patients with ischemic stroke with subtypes of large artery atherosclerosis, small vessel occlusion and cardioembolism who admitted at the SNUH between November 2014 and November 2017 were screened. We excluded the patient who have a history of secondary hypertension, CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m 2 ), valvular heart disease, congenital heart disease, dilated or hypertrophy cardiomyopathy and thyroid disease. Results: Among the total 627 patients, 61.8% were male, with a mean age of 67.9 years. Compared to the other stroke mechanisms, a stepwise logistic regression analysis showed that AF was independently associated with size of left atrium (OR, 1.196, 95% CI: 1.160-1.266), initial stroke severity (NIH Stroke Scale) (OR, 1.126, 95% CI: 1.083-1.189), and Cys-C (OR, 2.472, 95% CI: 1.255-15.129), but not with eGFR (OR 0.993, 95% CI: 0.977-1.009). Conclusion: Cys-C is a superior predictor for cardioembolic stroke due to AF in patients without evident CKD.